Navigation Links
Insmed Inc. Welcomes Studies Linking IGFBP-3 to Prevention of,Blindness in Premature Infants

RICHMOND, Va.--(BUSINESS WIRE)--Jun 26, 2007 - Insmed Incorporated (Nasdaq:INSM), a biopharmaceutical company focused on the development and approval of drugs for the treatment of metabolic diseases with unmet medical needs, today noted the publication of promising results of research from three universities regarding the potential role of insulin-like growth factor binding protein-3 (IGFBP-3) in the prevention of blindness among premature infants.

IGFBP-3 is a key component of Insmed's lead drug candidate, IPLEX(TM), which has been approved by the U.S. Food and Drug Administration for the treatment of a severe growth disorder and is currently being studied as a treatment for myotonic muscular dystrophy, HIV-associated adipose redistribution syndrome and retinopathy of prematurity (ROP). IPLEX(TM) is the combination of IGFBP-3 with recombinant human insulin-like growth factor 1 (IGF-I).

The new study results, published in the June 19 issue of the Proceedings of the National Academy of Sciences, focus on the action of IGFBP-3 in promoting normal tissue growth and preventing ROP. Researchers at the University of Florida reported that mice treated with IGFBP-3 showed closer-to-normal growth of retinal vasculature than mice without IGFBP-3 in similar high-oxygen conditions. Researchers at Harvard Medical School and the University of Goteborg in Sweden reported similar results.

In addition, Harvard Medical School researchers, in collaboration with researchers at the University of Goteborg, reported results of a clinical study showing IGFBP-3 levels in infants with ROP were lower than those of healthy babies. The researchers said these results suggest that IGFBP-3, acting independently of IGF-I, helps prevent oxygen-induced loss of blood-vessels and helps promote vascular re-growth.

Insmed Chairman and CEO Geoffrey Allan, Ph.D., commented: "These studies by researchers at three distinguished univ ersities mark an important scientific milestone in Insmed's development of IPLEX(TM) as a treatment for ROP. They suggest that IGFBP-3, once thought only to regulate IGF-I, actually plays a broader role in human development and in the growth or regeneration of human tissues. Not only is this discovery important in the fight against ROP, but it also suggests promising avenues for research into the treatment of other conditions associated with ischemia and vascular damage."

About IPLEX(TM) and ROP

IPLEX(TM) is currently in the first phase of clinical development for the treatment of ROP, a disease that affects an estimated 14,000 to 16,000 premature infants each year. ROP impedes the development of the small blood vessels in the back of the eye, leading to blindness in severe cases. A Phase I clinical study investigating IPLEX(TM) as a treatment for ROP is underway at the University of Goteborg, in collaboration with scientists at the Harvard Medical School. Ten patients will be enrolled with the objective of the study being to determine the dose of IPLEX(TM) required to increase serum IGF-I levels into the normal physiological range. This study is expected to be completed by the end of 2007.

About Insmed

Insmed is a biopharmaceutical company focused on the development and approval of drugs for the treatment of metabolic diseases with unmet medical needs. For more information, please visit www.insmed.com. To be added to Insmed's investor lists, please contact Haris Tajyar at htajyar@irintl.com or at 818-382-9702.

Forward Looking Statements

This release contains forward-looking statements which are made pursuant to provisions of Section 21E of the Securities Exchange Act of 1934. Investors are cautioned that such statements in this release, including statements relating to planned clinical study design, regulatory and business strategies, plans and objectives of management and growth opportunities for existing or proposed produ cts, constitute forward-looking statements which involve risks and uncertainties that could cause actual results to differ materially from those anticipated by the forward-looking statements. The risks and uncertainties include, without limitation, risks that product candidates may fail in the clinic or may not be successfully marketed or manufactured, the Company may lack financial resources to complete development of product candidates, the FDA may interpret the results of studies differently than the Company, competing products may be more successful, demand for new pharmaceutical products may decrease, the biopharmaceutical industry may experience negative market trends and other risks and challenges detailed in the Company's filings with the U.S. Securities and Exchange Commission, including the Company's Quarterly Report on Form 10-Q for the quarter ended March 31, 2007. Readers are cautioned not to place undue reliance on any forward-looking statements which speak only as of the date of this release. The Company undertakes no obligation to publicly release the results of any revisions to these forward-looking statements that may be made to reflect events or circumstances that occur after the date of this release or to reflect the occurrence of unanticipated events.

Contact

Investor Relations International
Haris Tajyar, 818-382-9702
htajyar@irintl.com


'"/>




Related medicine technology :

1. Insmed Inc. to Present at C.E. Unterberg, Towbin Growth Conference
2. Insmed Announces Promising Results From IPLEX Phase II Myotonic Muscular Dystrophy Clinical Study
3. Insmed Releases Positive Results from Iplex Phase II HIV-Associated Adipose Redistribution Syndrome Clinical Study
4. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
5. NexMed Announces Completion of Patient Enrollment in Two Pivotal Phase 3 Studies for Anti-Fungal Product
6. Studies of Drug Resistance May Lead to Individual Therapy for Rare Cancers
7. Cyclacel Pharmaceuticals Announces Results of Phase II Seliciclib Combination Studies
8. Resveratrol Studies Suggest Broad Implications for SIRT1 Activation in Neurodegenerative Diseases of Aging Such as Alzheimers Disease
9. Publication on Pixantrone Preclinical Studies Demonstrates Reduced Cardiotoxicity Compared to Equiactive Doses of Doxorubicin and Mitoxantrone
10. Phosphagenics Announces Positive Proof of Concept Results from Studies Utilizing Companys Dermal Drug Delivery Technology
11. New Data from Multiple Studies Show Galvus Delivers Consistent and Robust Blood Sugar Control in Patients with Type 2 Diabetes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/24/2017)... Today Stock-Callers.com have issued research reports on four ... NVCN), Hologic Inc. (NASDAQ: HOLX), Edwards Lifesciences Corp. (NYSE: EW), ... companies are part of the Healthcare sector, which gave back ... , 2017, with the NYSE Health Care Index declining 0.2% ... the S&P 500 were down about 0.4% as a group. ...
(Date:3/24/2017)... 2017  GenomeDx Biosciences today announced that six abstracts ... Prostate Cancer Classifier tests will be presented at the ... Congress held March 24 to 28, 2017 in ... is Europe,s largest urological event ... urological field. The abstract titled "Muscle invasive ...
(Date:3/24/2017)...  HealthMine surveys with 9,250 insured consumers fielded from ... members want help from their plans in five key ... health, 2) help closing gaps in care, 3) better ... 5) relevant, real-time guidance. Meeting these needs is essential ... A Reason to Stay Engaged in ...
Breaking Medicine Technology:
(Date:3/24/2017)... ... ... Texas Physical Therapy Specialists (TexPTS) is pleased to announce the opening ... is the group’s 7th location in San Antonio and 23rd in Texas. Dr. ... from the clinic, which opened March 22, 2017. , The team of ...
(Date:3/24/2017)... Pittsburgh, PA (PRWEB) , ... March 24, 2017 ... ... the Oncology Nursing Society (ONS) wanted to create a communications platform that positions ... realize this goal, Elliance and ONS reinvented their online publication as an always-on, ...
(Date:3/24/2017)... (PRWEB) , ... March 24, 2017 , ... ... ( http://www.hygieacare.com ) announced their partnership to prep patients for colonoscopy at the ... Endoscopy Centers in 87th Ave., Miami, FL. , The HyGIeaCare® Prep, ...
(Date:3/24/2017)... ... ... “Vintage and Harvest A Cultivation of Christian Love” is the creation of published author, ... his wife, Anna Marie. He and his wife are the proud parents of four ... of “Shadow and Substance.” , “Love, the agape kind, is seen as more than ...
(Date:3/23/2017)... ... 2017 , ... The physicians of KSF Orthopaedic Center PA are proud to ... location is located at 2255 E. Mossy Oaks Rd., Suite 440, Spring, Texas 77389 ... provide patients living in the north Houston area (The Woodlands, Conroe, Magnolia, Kingwood, Humble) ...
Breaking Medicine News(10 mins):